MEDIOCON INC – Ladostigil is a synthetic multifunctional investigational compound also known as TV-3326. It was developed as a dual inhibitor of cholinesterase and monoamine oxidase (MAO), with additional reported neuroprotective, antioxidant and anti-inflammatory properties. It has been investigated primarily in research related to neurodegenerative disorders, including Alzheimer's disease and depression.
Ladostigil is a carbamate-derived small molecule designed to act on multiple neurological pathways. It inhibits cholinesterase and brain-selective monoamine oxidase activity and has been investigated as a multifunctional approach to neurodegenerative disease research.
Ladostigil is identified by CAS 209394-27-4, molecular formula C₁₆H₂₀N₂O₂, and molecular weight 272.34 g/mol.
Product Name: Ladostigil
CAS Number: 209394-27-4
Molecular Formula: C₁₆H₂₀N₂O₂
Molecular Weight: 272.34 g/mol
Chemical Class: Carbamate / Multifunctional neuroactive compound
Development Code: TV-3326
PubChem CID: 208907
IUPAC Name: [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate
Synonyms: TV-3326, TV3326, Ladostigil Free Base
The chemical identity and CAS number are consistently reported by specialist chemical databases and research suppliers.
Ladostigil is described as a dual inhibitor of cholinesterase and monoamine oxidase (MAO). Research data report inhibitory activity against MAO-B and acetylcholinesterase (AChE). It has also been investigated for potential neuroprotective, antioxidant and anti-inflammatory effects.
MEDIOCON INC focuses on supplying pharmaceutical and specialty chemical ingredients with emphasis on quality, consistency, technical documentation and reliable supply.
Ladostigil quality evaluation may include identification, assay, chromatographic purity, related substances, residual solvents, water content, residue on ignition and other parameters according to the applicable product specification.
The exact analytical acceptance criteria should be confirmed against the current approved specification and batch-specific Certificate of Analysis.
Ladostigil has been investigated in neurodegenerative disease research, particularly research associated with Alzheimer's disease, cognitive dysfunction and depression.
Because Ladostigil is an investigational compound, it should be presented on the website as a research/development compound, not as an approved therapeutic medicine.
Ladostigil is generally supplied as a solid/powder at room temperature. Research-product documentation identifies it as a solid and recommends powder storage at controlled low temperature.
Appearance: White to off-white powder / solid
Product availability, packaging configuration, Certificate of Analysis (COA), Safety Data Sheet (SDS/MSDS), technical specifications and other documentation should be confirmed with MEDIOCON INC according to the intended application and customer requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white powder |
| Assay (HPLC) | >98.0% |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Ladostigil API Manufacturer and Supplier in India (CAS 209394-27-4) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Ladostigil API Manufacturer and Supplier in India is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing before release with a Certificate of Analysis.
Export Markets
Quality & Compliance